P965: FOLLOW-UP ANALYSIS OF THE RANDOMIZED PHASE II TRIAL OF BORTEZOMIB, LENALIDOMIDE, DEXAMTHASONE WITH/WITHOUT ELOTUZUMAB FOR NEWLY DIAGNOSED, HIGH RISK MULTIPLE MYELOMA (SWOG-1211)
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-06-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000846728.05693.f8 |
| _version_ | 1827336360752578560 |
|---|---|
| author | S. Usmani A. Hoering S. Ailawadhi R. Sexton B. Lipe J. Valent M. Rosenzweig J. Zonder M. Dhodapkar N. Callander T. Zimmerman P. Voorhees B. Durie S. V. Rajkumar P. Richardson R. Orlowski |
| author_facet | S. Usmani A. Hoering S. Ailawadhi R. Sexton B. Lipe J. Valent M. Rosenzweig J. Zonder M. Dhodapkar N. Callander T. Zimmerman P. Voorhees B. Durie S. V. Rajkumar P. Richardson R. Orlowski |
| author_sort | S. Usmani |
| collection | DOAJ |
| first_indexed | 2024-03-07T18:30:16Z |
| format | Article |
| id | doaj.art-c2f21220f24849ceb2ed8389d8158765 |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T18:30:16Z |
| publishDate | 2022-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-c2f21220f24849ceb2ed8389d81587652024-03-02T06:40:50ZengWileyHemaSphere2572-92412022-06-01685585610.1097/01.HS9.0000846728.05693.f8202206003-00855P965: FOLLOW-UP ANALYSIS OF THE RANDOMIZED PHASE II TRIAL OF BORTEZOMIB, LENALIDOMIDE, DEXAMTHASONE WITH/WITHOUT ELOTUZUMAB FOR NEWLY DIAGNOSED, HIGH RISK MULTIPLE MYELOMA (SWOG-1211)S. Usmani0A. Hoering1S. Ailawadhi2R. Sexton3B. Lipe4J. Valent5M. Rosenzweig6J. Zonder7M. Dhodapkar8N. Callander9T. Zimmerman10P. Voorhees11B. Durie12S. V. Rajkumar13P. Richardson14R. Orlowski151 Memorial Sloan Kettering Cancer Center, New York2 Cancer Research And Biostatistics, Seattle3 Mayo Clinic, Jacksonville2 Cancer Research And Biostatistics, Seattle4 University of Rochester Medical Center, Rochester, NY5 Cleveland Clinic, Cleveland6 City of Hope, Los Angeles7 Karmanos Cancer Institute, Detroit, MI8 Emory Winship Cancer Institute, Atlanta GA9 University of Wisconsin, Madison10 Beigene, Chicao11 Levine Cancer Institute, Charlotte12 Cedar Sinai Medical Center, Los Angeles13 Mayo Clinic, Rochester MN14 Dana Farber Cancer Institute, Boston MA15 MD Anderson Cancer Center, Houston TX, United States of Americahttp://journals.lww.com/10.1097/01.HS9.0000846728.05693.f8 |
| spellingShingle | S. Usmani A. Hoering S. Ailawadhi R. Sexton B. Lipe J. Valent M. Rosenzweig J. Zonder M. Dhodapkar N. Callander T. Zimmerman P. Voorhees B. Durie S. V. Rajkumar P. Richardson R. Orlowski P965: FOLLOW-UP ANALYSIS OF THE RANDOMIZED PHASE II TRIAL OF BORTEZOMIB, LENALIDOMIDE, DEXAMTHASONE WITH/WITHOUT ELOTUZUMAB FOR NEWLY DIAGNOSED, HIGH RISK MULTIPLE MYELOMA (SWOG-1211) HemaSphere |
| title | P965: FOLLOW-UP ANALYSIS OF THE RANDOMIZED PHASE II TRIAL OF BORTEZOMIB, LENALIDOMIDE, DEXAMTHASONE WITH/WITHOUT ELOTUZUMAB FOR NEWLY DIAGNOSED, HIGH RISK MULTIPLE MYELOMA (SWOG-1211) |
| title_full | P965: FOLLOW-UP ANALYSIS OF THE RANDOMIZED PHASE II TRIAL OF BORTEZOMIB, LENALIDOMIDE, DEXAMTHASONE WITH/WITHOUT ELOTUZUMAB FOR NEWLY DIAGNOSED, HIGH RISK MULTIPLE MYELOMA (SWOG-1211) |
| title_fullStr | P965: FOLLOW-UP ANALYSIS OF THE RANDOMIZED PHASE II TRIAL OF BORTEZOMIB, LENALIDOMIDE, DEXAMTHASONE WITH/WITHOUT ELOTUZUMAB FOR NEWLY DIAGNOSED, HIGH RISK MULTIPLE MYELOMA (SWOG-1211) |
| title_full_unstemmed | P965: FOLLOW-UP ANALYSIS OF THE RANDOMIZED PHASE II TRIAL OF BORTEZOMIB, LENALIDOMIDE, DEXAMTHASONE WITH/WITHOUT ELOTUZUMAB FOR NEWLY DIAGNOSED, HIGH RISK MULTIPLE MYELOMA (SWOG-1211) |
| title_short | P965: FOLLOW-UP ANALYSIS OF THE RANDOMIZED PHASE II TRIAL OF BORTEZOMIB, LENALIDOMIDE, DEXAMTHASONE WITH/WITHOUT ELOTUZUMAB FOR NEWLY DIAGNOSED, HIGH RISK MULTIPLE MYELOMA (SWOG-1211) |
| title_sort | p965 follow up analysis of the randomized phase ii trial of bortezomib lenalidomide dexamthasone with without elotuzumab for newly diagnosed high risk multiple myeloma swog 1211 |
| url | http://journals.lww.com/10.1097/01.HS9.0000846728.05693.f8 |
| work_keys_str_mv | AT susmani p965followupanalysisoftherandomizedphaseiitrialofbortezomiblenalidomidedexamthasonewithwithoutelotuzumabfornewlydiagnosedhighriskmultiplemyelomaswog1211 AT ahoering p965followupanalysisoftherandomizedphaseiitrialofbortezomiblenalidomidedexamthasonewithwithoutelotuzumabfornewlydiagnosedhighriskmultiplemyelomaswog1211 AT sailawadhi p965followupanalysisoftherandomizedphaseiitrialofbortezomiblenalidomidedexamthasonewithwithoutelotuzumabfornewlydiagnosedhighriskmultiplemyelomaswog1211 AT rsexton p965followupanalysisoftherandomizedphaseiitrialofbortezomiblenalidomidedexamthasonewithwithoutelotuzumabfornewlydiagnosedhighriskmultiplemyelomaswog1211 AT blipe p965followupanalysisoftherandomizedphaseiitrialofbortezomiblenalidomidedexamthasonewithwithoutelotuzumabfornewlydiagnosedhighriskmultiplemyelomaswog1211 AT jvalent p965followupanalysisoftherandomizedphaseiitrialofbortezomiblenalidomidedexamthasonewithwithoutelotuzumabfornewlydiagnosedhighriskmultiplemyelomaswog1211 AT mrosenzweig p965followupanalysisoftherandomizedphaseiitrialofbortezomiblenalidomidedexamthasonewithwithoutelotuzumabfornewlydiagnosedhighriskmultiplemyelomaswog1211 AT jzonder p965followupanalysisoftherandomizedphaseiitrialofbortezomiblenalidomidedexamthasonewithwithoutelotuzumabfornewlydiagnosedhighriskmultiplemyelomaswog1211 AT mdhodapkar p965followupanalysisoftherandomizedphaseiitrialofbortezomiblenalidomidedexamthasonewithwithoutelotuzumabfornewlydiagnosedhighriskmultiplemyelomaswog1211 AT ncallander p965followupanalysisoftherandomizedphaseiitrialofbortezomiblenalidomidedexamthasonewithwithoutelotuzumabfornewlydiagnosedhighriskmultiplemyelomaswog1211 AT tzimmerman p965followupanalysisoftherandomizedphaseiitrialofbortezomiblenalidomidedexamthasonewithwithoutelotuzumabfornewlydiagnosedhighriskmultiplemyelomaswog1211 AT pvoorhees p965followupanalysisoftherandomizedphaseiitrialofbortezomiblenalidomidedexamthasonewithwithoutelotuzumabfornewlydiagnosedhighriskmultiplemyelomaswog1211 AT bdurie p965followupanalysisoftherandomizedphaseiitrialofbortezomiblenalidomidedexamthasonewithwithoutelotuzumabfornewlydiagnosedhighriskmultiplemyelomaswog1211 AT svrajkumar p965followupanalysisoftherandomizedphaseiitrialofbortezomiblenalidomidedexamthasonewithwithoutelotuzumabfornewlydiagnosedhighriskmultiplemyelomaswog1211 AT prichardson p965followupanalysisoftherandomizedphaseiitrialofbortezomiblenalidomidedexamthasonewithwithoutelotuzumabfornewlydiagnosedhighriskmultiplemyelomaswog1211 AT rorlowski p965followupanalysisoftherandomizedphaseiitrialofbortezomiblenalidomidedexamthasonewithwithoutelotuzumabfornewlydiagnosedhighriskmultiplemyelomaswog1211 |